FDA Expands Stelara Approval; Liver Cancer Blood Test; Pharmacotherapy for MASLD
The FDA expanded the approval of ustekinumab (Stelara) in Crohn’s disease to include the treatment of kids as young as 2 years, Johnson & Johnson announced. High clinical remission rates (98%) at approximately 5 years were reported with guselkumab (Tremfya) maintenance in Crohn’s disease, long-term follow-up of the phase II GALAXI-1 trial showed. (Inflammatory Bowel…
